Foster & Motley Inc. Purchases New Position in Becton, Dickinson and Company $BDX

Foster & Motley Inc. bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 5,452 shares of the medical instruments supplier’s stock, valued at approximately $825,000.

A number of other institutional investors have also added to or reduced their stakes in BDX. Imprint Wealth LLC bought a new position in shares of Becton, Dickinson and Company in the third quarter valued at approximately $25,000. SHP Wealth Management purchased a new stake in Becton, Dickinson and Company during the fourth quarter valued at about $26,000. Meeder Asset Management Inc. raised its holdings in Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 102 shares during the period. Main Street Group LTD purchased a new stake in Becton, Dickinson and Company during the 1st quarter worth about $29,000. Finally, Bell Investment Advisors Inc bought a new stake in Becton, Dickinson and Company during the 2nd quarter worth approximately $29,000. 86.97% of the stock is owned by institutional investors.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the transaction, the executive vice president directly owned 13,172 shares of the company’s stock, valued at $1,918,633.52. The trade was a 7.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 11,779 shares of company stock valued at $1,974,669 over the last quarter. 0.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently commented on BDX. Wells Fargo & Company increased their price target on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Evercore set a $180.00 price target on shares of Becton, Dickinson and Company in a research report on Monday, July 6th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. TD Cowen increased their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. Finally, Piper Sandler boosted their target price on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $185.67.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $187.82 on Thursday. The firm has a market capitalization of $51.75 billion, a PE ratio of 56.57, a P/E/G ratio of 12.74 and a beta of 0.19. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The company has a 50 day moving average price of $159.86 and a 200-day moving average price of $161.02. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.96.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The firm had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The company’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period last year, the business posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities research analysts expect that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 126.51%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.